disclaim financi forecast recommend current review
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim feb
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
uniqu busi impress histor result
compani strategi reli success manag
continu capit alloc acumen integr effort
underli
busi perform conserv use financ suggest
compani remain disciplin strategi risk
recent deal like pall nobel cepheid brought
innov industri leader higher growth opportun
expens return capit taken slide
recent year mostli like long-term outlook
major busi wed like see
evid manag wont overpay growth
follow spin-off anticip spin-off
dental segment becom major player
life scienc diagnost market continu
appreci direct manag capit deploy
life scienc
diagnost remain attract area age
popul demograph growth person medicin
demand biolog manufactur process instal
equip help maintain sticki custom base recur
healthi cash flow proce dental spin see
number potenti avenu manag continu
deploy capit boost competit edg diagnost
exampl gain access molecular diagnost
cepheid deal manag may want
enhanc exposur molecular genom test life
scienc side could boost chromatographi
imagin spin-off dental segment stem
segment weak perform although dental industri
exposur mostli cash pay servic combin fragment
custom base remain attract attribut market rise
corpor practic buy power increas commodit
mani product categori weaken growth profit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
spin-off diversifi mostli
healthcare-focus instrument suppli manufactur spin
dental environment appli solut segment repres
approxim revenu respect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
place review transfer
coverag new analyst expect publish new fair
valu estim second quarter
increas fair valu estim
per share make slight adjust
model well cash flow realiz sinc last
multipl approxim
forecast averag annual organ growth
danah next five year nearli organ
growth life scienc diagnost segment
offset slower growth dental environment
appli segment expect danah abl
maintain low mid-single-digit organ growth
product segment life scienc diagnost
divis repres higher growth opportun
model small tuck-in acquisit minor contribut
sale growth acknowledg larger
unpredict deal like drive higher growth
expens capit deploy firm
forecast oper margin rise
near next five year
integr pall cepheid along on-going cost
save effort lead consider margin expans
life scienc diagnost segment expect
much margin improv environment
appli solut busi alreadi post oper
margin assumpt result return
invest capit gradual rise back
estim cost capit approxim
danah diversif presenc mani stabl
industri reduc compani overal risk view
manag consist strategi creat
meaning integr overpay risk manag
abil integr pall continu turnaround nobel
oper improv cepheid profit
larg bear near-term perform exampl
fair valu estim bull case
assum stronger organ growth help part better
macroeconom condit lead higher spend
equip dental procedur lead annual
organ growth next five year also
forecast better-than-expect integr result
deal -- particularli pall cepheid -- result oper
margin near return capit also rise
midteen scenario
persist weak global macroeconom condit
manag inabl spur higher growth
product develop market effort result
rel lacklust total annual organ growth
next five year worse-than-expect integr
effort addit weak top-lin perform doesnt
allow manag effici scale oper lead
modest margin expans high-teen
return capit also bare reach
bear case scenario result fair valu estim
maintain narrow-moat rate danah
follow spin-off includ
test measur oper fluke tektronix
root industri technolog segment
kollmorgen thomson jacob vehicl danah
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
includ legaci beckman coulter sciex leica
pall cepheid busi rel high switch
cost larg instal base equip becom
essenti compon custom workflow system
stabl instal base equip support consist
pull consum make bulk
sale divis
intend spin-off dental segment
includ implant acquir nobel deal
orthodont ormco specialti dental product
gener sold directli specialist demand newer
innov technolog high qualiti materi
addit remain hesit switch brand due
previou train also major player dental
although typic market leader
product categori compani remain larg
signific player industri innov
sticki relationship help preserv compani
brand number four player diagnost
exampl compet heavili roch
siemen abbott high volum clinic chemistri
immunoassay market also contend
hematolog compet sysmex anatom
patholog compet primarili roch
agil molecular diagnost asset acquir
cepheid pit compani player like roch
biomerieux second largest
dental player dentspli recent acquisit
nobel make compani one key innov
premium implant market filtrat water
busi compet compani like ge siemen
among other
think danah moat trend stabl dont forese
major disrupt technolog risk competit headwind
remain diversifi predomin healthcare-focus
busi retain life scienc diagnost dental
water qualiti product
recur consum revenu make
benefit
predomin switch cost intang asset
also like gain modest benefit economi
scale layer adjac busi roll-up
acquisit gain consolid
improv sell distribut
purchas
effici compet
mani
commodit market howev differenti product
innov meet custom need remain
critic moat sourc view
 strategi continu focu mostli nich
oligopolist market high barrier entri creat
combin complex
instrument high switch cost extens brand
recognit nearli revenu spin-off
life scienc diagnost segment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
compani market modest innov
keep competit advantag stabl
manag like continu use acquisit fill
area compani lack industri presenc
recent cepheid deal attain access
bolster life scienc diagnost oper
expand product breadth build greater
capabl area ga liquid chromatographi
although plan spin-off dental busi
think segment face greatest risk
competit pressur equip
specialti dental product help partial insut
compani competit think dental industri
overal face increas commodit price
pressur cheaper altern custom exert
buy power supplier
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
post impress track record
deal enabl compani creat
competit busi boost asset
perform focu improv effici
market leadership
 strategi find busi
attract healthcar market led roic declin
year especi pursuit implant
manufactur nobel filtrat purif
odanah shift healthcar market creat less
cyclic busi attract market high
entri
plenti opportun consolid
improv perform variou fragment
nich healthcar market especi life scienc
diagnost
outstand leader
market roch siemen repres larger
potenti innov competit
osom market
exampl nobel previous suffer low
price open sourc competit lucr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
strategi think compani maintain rel healthi
financ thank compani strong oper cash flow
combin fairli conserv use credit equiti
financ transact compani debt balanc
consider increas financ pall acquisit
follow cepheid acquisit
debt remain manag firm produc
healthi cash flow cover debt oblig pay small
time end danah ebitda interest
coverag ratio histor remain time
compani dividend yield
danah diversif presenc mani stabl
industri reduc compani overal risk view
manag consist strategi creat
meaning integr overpay risk manag
abil integr pall continu turn around nobel
oper improv cepheid profit
larg bear near-term perform exampl
think aggress strategi creat
risk compani particularli manag begin
consist overpay asset integr effort
larg busi fail make gain materi danah
on-going shift healthcar also expos firm
market requir consist innov howev
manag stabl histori integr busi
sustain growth profit leverag
balanc sheet help keep risk
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
compani moder level risk
compani histor perform sharehold
align manag make danah fairli
shareholder-friendli firm view although recent
declin return capit reason concern
favor view manag histor capit
alloc decis focus asset
industri certain attract characterist
combin manag abil improv oper
perform danah busi system
system continu improv empow leadership
focus custom need combin
enabl becom major player mani
attract market materi improv mani
acquir busi impair rare
compani support view manag follow
disciplin strategi process think dental
segment manag intend spin
one area under-perform
compani recent histori manag may stuck
busi long given recent competit
headwind applaud decis separ
co-found brother mitchel steven rale retain
influenc compani creat
mitchel rale chairman execut committe
steven rale chairman board also
cumul approxim outstand
share thoma joyc join becam
ceo follow mani previou leadership posit
compani recent water qualiti life
scienc diagnost segment joyc also join rale
brother compani board donald ehrlich
lead independ director board sinc
matthew mcgrew --
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
previous led financ firm diagnost dental
divis -- replac daniel coma cfo
compani transit retir director
elect annual execut compens mostli tie
adjust ep target also includ free cash flow ratio
return invest capit metric wed prefer return
capit play larger role determin compens
 heavi firm like think
compani compens structur fairli shareholder-friendli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mostli favor outlook danah plan
acquir biopharma busi billion
approxim billion includ expect
billion tax benefit mani way acquisit isnt major
surpris sinc busi fit mold danah
strateg direct -- high growth high margin busi
larg stream consum sticki custom
product chromatographi system biopharma
asset share signific amount strateg overlap
danah exist life scienc busi overal dont
expect dramat shift fair valu estim
incorpor acquisit model also
dont expect chang narrow moat rate view
transact increment posit danah
think purchas price impli roughli time
ebitda look fair especi given segment high
exposur biopharma custom group boost
danah exposur attract portion life
scienc market biopharma custom segment
offer higher growth outlook thank demand biolog
drug develop manufactur also sticker
base user around regul input approv
pharmaceut product manag expect
growth asset may conserv
manag like priorit invest higher
growth portion busi single-us
technolog gene therapi product
thank larg part larg consum mix near
sale alreadi high profit manag
see million cost synergi three year
impli impress ebitda margin near
manag also expect initi boost
adjust ep first year like doubl within five
past year purchas
life scienc diagnost market
manag will take long-term view return
invest capit high single-digit return expect
five year
lastli expect deal close fourth
quarter financ deal cash hand new debt
issu near billion equiti like
inherit pension liabil ge manag
expect bbb credit rate follow transact
manag also announc intend ipo
dental busi -- potenti share initi
issu -- rather previou spin-off plan
bear window narrow thesi play ge
sell biopharma feb
agre sell biopharma busi
approxim billion includ billion cash
assumpt certain pension liabil time
forward ebitda specul deal
possibl earli last year wrote deal would
approxim billion current forward enterpris
value/ebitda multipl unit join
danah life scienc stand-alon busi
pharmaceut diagnost current form part
ge life scienc stay remaind ge
healthcar busi suppli contrast media
molecular imag consum radiolog custom
carve-out clearli make sens us given synergi
remain ge healthcar core medic imag
busi still evalu full impact
transact mostli time overli surpris
deal dont expect materi chang ge
fair valu estim per share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
express interest busi earli
spring report wall street journal
time howev ge reportedli interest
pursu deal ge lose one bright star
typic increas top line high-single-digit
year-over-year clip think ceo larri make
right strateg decis first deal may make
life scienc valuat current high deal offer
team opportun de-lever balanc
sheet second believ ge life scienc littl
strateg valu futur industri infrastructur
final perhap importantli asset price discoveri
valuabl asset rel line
expect contrast bear assert ge
forc fire sale desir asset
dig self-impos debt hole
believ bear argument
particularli concern ge capit liabil thu
far seem less pronounc initi fear furthermor
ge gener adjust industri free cash flow
billion oper futur remain
strain power believ confirm thesi
ge highli desir asset exceed current
expect fulli valu time
ge transport merger close feb
updat explicit forecast expect
concurr file week
though currenc tariff repres small hurdl
plan make adjust model narrow-
moat compani fourth-quart result
larg keep compani line expect
manag outlook adjust ep
initi forecast think like
compani start year conserv tone
especi modest headwind china-rel
tariff combin neg currenc effect econom
growth concern china also dont seem affect
compani far manag note on-going broad-
base double-digit growth countri quarter
recent result expect organ
growth quarter life scienc segment
remain highest growth divis thank larg part
growth beckman life scienc sciex phenomenex
pall segment pall particular continu wit
double-digit growth among biotech custom group
rate manag note greater stabil
 market healthi perform china
still earli stage launch clear align
busi could add nice tailwind dental
segment lead expect spin-off busi
later year lastli growth diagnost
growth environment appli segment mostli
match forecast
fourth-quart oper margin bit
weaker anticip basi point
form last year dont anticip materi shift
futur profit assumpt addit acquisition-
currency- tariff-rel pressur bottom line
also
invest certain
initi clear align opportun dental
segment regardless long term still see
integr effici improv effort well
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
life scienc diagnost industri offer attract
growth moat wari valuat
think plenti like life scienc
sever competit advantag lead econom
moat industri tend predict
attract growth outlook especi area
bioprocess analyt instrument genom
addit somewhat insul broader
macroeconom cycl nearli everi compani life
scienc diagnost manufactur coverag also earn
econom moat thank intang often pair
high switch cost valuat alreadi reflect
optim howev multipl across industri
look expens view current think water
agil becton dickinson reflect best
valu trade close territori view mettler
biomerieux significantli overvalu
moat common life scienc tool thank intang
switch cost gener award moat life
scienc diagnost firm record consist
innov larg instal base equip
dedic pull consum
chromatographi mass spectrometri market led
water agil creat one wide-moat
segment benefit low disrupt risk high
barrier entri comfort oligopoli razor-and-
blade busi model high custom switch cost
nich ga
outlook life scienc diagnost market
remain stabl attract pocket growth
estim market exce roughli billion grow
nearli annual depend market
segment popul growth increas drug research
volum workflow improv rise manufactur
qualiti standard emerg field genet research
test key industri growth driver
complet overview life scienc moat analysi
pleas see report life scienc diagnost industri
offer attract growth econom moat wari
valuat discuss growth outlook
econom moat life scienc industri
danah life scienc environment unit
off-set diagnost dental weak oct
report anoth fairli stabl quarter across
busi segment especi neg currenc
effect top bottom line intern revenu growth
oper margin improv
basi point last year put compani
track slightli outperform previou forecast
manag rais year-end adjust ep outlook
look
achiev us given perform first three
quarter year although rais fair valu
estim per share slightli increas near-
term organ growth expect combin time
valu money sinc last updat still think
danah share look modestli overvalu asid
dental segment think danah narrow moat remain
good shape especi life scienc diagnost
summar thought quarter life scienc
well environment appli segment exceed
expect off-set weaker result diagnost
dental divis life scienc segment --
organ growth basi point segment margin
expans -- post particularli strong result view
thank larg part double-digit growth bioprocess
single-us technolog among biopharma custom
legaci pall busi life scienc unit also
post high-singl digit growth suggest potenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
market share gain meanwhil doubl digit growth
water qualiti oper within environment
appli segment especi demand china led
perform divis
manag increas invest dental busi
target specialti segment well ramp
clear align busi specif target
stronghold area
meanwhil diagnost divis neg
affect currenc movement weak
develop market within beckman coulter busi
quarter organ growth nearli
basis-point oper margin declin weaker
anticip manag note healthier perform
diagnost unit cepheid sustain double-
digit growth hard know chang medicar
clinic lab fee schedul might sap
demand diagnost product especi
matur clinic chemistri hematolog portion
market manag highlight weak
still think segment overal noteworthi growth
margin expans opportun ahead follow
cepheid acquisit still think manag
eventu look deploy capit genom test
portion market gain access higher growth
condit remain weak dental segment
manag continu suggest outlook improv
organ revenu fell quarter nearli
basis-point declin oper margin thank part
currenc effect invest prepar divis
expect spin-off second half still
surpris weak perform segment
support decis separ busi due
likelihood increas competit market time
includ greater buy power corpor account
buy group well rise low-pric competit
tradit consum equip remain
sore spot compani post stabl growth
specialti orthodont implant product categori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
